LQ23 is a selective inhibitor of CDC2-like kinase 2 (CLK2) with IC50 of 1.4 nM. LQ23 exhibits anti-inflammatory activity.

Physicochemical Properties

Molecular Formula	C24H24N4OS
Molecular Weight	416.54
CAS #	2997615-62-8
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	IC50: 1.4 nM (CLK2), 2.1 nM (CLK1), 3.2 nM (CLK4), 21.7 nM (DYRK1A), >100 nM (CLK3)
ln Vitro	LQ23 (10-100 nM) dose-dependently inhibits SR protein phosphorylation in chondrocytes, thereby regulating the selective cleavage of genes[1]. LQ23 (10-100 nM) dose-dependently inhibits CHIR99021-stimulated Wnt signaling in HEK-293T cells with an IC50 of 2.9 μM[1]. LQ23 (30 nM) improves osteoarthritis by promoting the differentiation of bone mesenchymal stem cells (BMSCs) into chondrocytes and inhibiting cartilage degradation[1].
ln Vivo	LQ23 (1.5 μg/kg, single intra-articular injection) inhibits inflammation, protects cartilage, and improves joint function in Sprague-Dawley rats with osteoarthritis induced by monosodium iodoacetate (MIA) or ACLT-pMMx [1].
Cell Assay	Western Blot Analysis[1] Cell Types: Chondrocytes Tested Tested Concentrations: 10-100 nM Incubation Duration: 1 h Experimental Results: Reduced phosphorylated SRSF4, SRSF5 and SRSF6. Reduced levels of β-catenin and c myc.
Animal Protocol	Animal/Disease Models: MIA-/ACLT-pMMx-induced osteoarthritis in Sprague-Dawley rats model[1] Doses: 1.5 μg/ kg Route of Administration: Single IA injection Experimental Results: Ameliorated the surface of the articular cartilage and the cell arrangement, reduced the thickness of the synovium, increased the gap between the femur and the tibia. Reduced the levels of inflammatory cytokines and catabolic enzymes.
References	[1]. Sun Y, Hu T, Zhang M, Song J, Qin Z, Liu M, Ji J, Li Z, Qiu Z, Bian J. Structure-Guided Discovery of Potent and Selective CLK2 Inhibitors for the Treatment of Knee Osteoarthritis. J Med Chem. 2024 Mar 28;67(6):4603-4623.

Solubility Data

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.4007 mL	12.0036 mL	24.0073 mL
	5 mM	0.4801 mL	2.4007 mL	4.8015 mL
	10 mM	0.2401 mL	1.2004 mL	2.4007 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.